When do tissues and cells become products? - Regulatory oversight of emerging biological therapies

Cell and Tissue Banking

Volumn 7, Issue 4, 2006, Pages 325-335

  Farrugia, Albert ^a  

^a THERAPEUTIC GOODS ADMINISTRATION   (Australia)

Author keywords

Cell therapies; Regulation; Tissues

Indexed keywords

ARTICLE; BIOLOGICAL THERAPY; CELL TRANSPLANTATION; DEVELOPED COUNTRY; DRUG INDUSTRY; GENE CONTROL; GOOD MANUFACTURING PRACTICE; HEALTH CARE ACCESS; HEALTH CARE FINANCING; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; INFECTION RISK; MATERIALS HANDLING; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL PRACTICE; METABOLIC REGULATION; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY CONTROL; RISK BENEFIT ANALYSIS; RISK REDUCTION; TISSUE TRANSPLANTATION;

BIOLOGICAL THERAPY; CELL TRANSPLANTATION; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DECISION MAKING; GOVERNMENT REGULATION; HUMANS; ORGAN TRANSPLANTATION; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; RISK ASSESSMENT;

EID: 33750892422     PISSN: 13899333     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10561-006-9012-1     Document Type: Article

References (36)

1. Center for Biologics Evaluation and Research (1997) Reinventing the regulation of human tissue. On http://www.fda.gov/cber/tissue/rego.htm Accessed 27/10/05
2. Center for Biologics Evaluation and Research (2002) Preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by human cells, tissues, and cellular and tissue-based products (HCT/Ps). On http://www.fda.gov/cber/gdlns/cjdvcjd0602.pdf Accessed 27/10/05
3. Center for Biologics Evaluation and Research (2004) Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products: Final rule and notice. On http://www.fda.gov/cber/ rules/suitdonor.pdf Accessed 27/10/05
4. Center for Biologics Evaluation and Research (2005) Frequently asked questions. On http://www.fda.gov/cber/faq.htm Accessed 27/10/05
5. Centers for Disease Control (2002) Update: Allograft-associated bacterial infections - United States, 2002. MMWR 51:207-210
6. Centers for Disease Control (2003) Hepatitis C virus transmission from an antibody-negative organ and tissue donor - United States 2000-2002. MMWR 52:273-276
7. Citron P (2004) Conflicts of interest are here to stay - implications for the medical device innovation process. On http://www.columbia-edu/ itc/hs/medical/bioethics/cire/conference/confMay04/monday/panelII/ citron.pdf Accessed 27/10/05
8. Council of Europe (2004) Recommendation Rec (2004) 8 of the Committee of Ministers to member states on autologous cord blood banks and explanatory memorandum. On http://www.coe.int/T/E/social_cohension/ health/recommendations/rec(2004)08.asp Accessed 27/10/05
9. Davis G, Wanna J, Warhurst J, Weller P (1993) Chapter 7: Making policy choices. In: Public policy in Australia, 2nd edn. Allen and Unwin, New South Wales, Australia
10. Dekkers W, Boers B (2001) Sham neurosurgery in patients with Parkinson's disease: Is it morally acceptable? J Med Ethics 27:151-156
11. Dzik S (2002) Non-infectious serious hazards of transfusion. Blood News May 2002. On http://www.unitedbloodservices.org/hospitalnewsletters/may/ 2002.pdf Accessed 27/10/05
12. Eastlund T (1995) Infectious disease transmission through cell, tissue and organ transplantation: Reducing the risk through donor selection. Cell Transplant 4:455-477
13. Eastlund T (2000) Hemodilution due to blood loss and transfusion and reliability of cadaver tissue donor infectious disease testing. Cell Tissue Bank 1:121-127
14. Farrugia A (2002) The regulatory pendulum in transfusion medicine. Transfus Med Rev 16:273-282
15. Food and Drug Administration (2002) Public health web notification: human tissue processed by Cryolife, Inc. On http://www.fda.gov/cdrh/ safety/humantissue.html Accessed 27/10/05
16. Greenwald MA (2005) Update on donor screening for TSEs. Presented at the 29th Annual Meeting, Council of Accredited Tissue Banks Tuesday 20 September 2005. On http://www.fda.gov/cber/summaries/aatb092005mg.pdf Accessed 27/10/05
17. Guyatt GH, Naylor D, Richardson WS, Green L, Haynes RB, Wilson MC, Cook DJ, Jaeschke RZ (2000) What is the best evidence for making clinical decisions? JAMA 284:3127-3128
18. Health Canada (2004) Notice to stakeholders - Regulatory framework for the safety of cells, tissues and organs for transplantation. On http://www.hc-sc.gc.ca/dhp-mps/brgtherap/reg-init/cell/ cto_let_stakeholders-intervenants_e.html Accessed 27/10/05
19. Hebert PC et al. (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in clinical care. N Engl J Med 340:409-417
20. Institute of Medicine (2005) Cord blood: Establishing a national hematopoietic stem cell bank program. Meyer EM, Hanna K, Gebbie K (eds)
21. Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Soo Lee D, Soho DW, Han KS, Oh BH, Lee MM, Park YB (2004) Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting. In myocardial infarction: The MAGIC cell randomised clinical trial. Lancet 363:751-756
22. Mitchell EJ et al. (2004) The effect of gamma irradiation sterilization on the fatigue crack propagation resistance of human cortical bone. JBJS(A) 86:2648-2657
23. Moore V. Regents of the University of California. On http://www.richmond.edu/~wolf/moore.htm Accessed 27/10/05
24. News Target Network (2004) FDA fails to protect public from dangerous drugs. http://www.newstarget.com/002325.html. Accessed 21/07/05
25. Rozem DL (2005) The FDA and IP regulatory issues surrounding the stem cell initiative. On http://www.foley.com/files/tbl_s31Publications/ FileUpload137/2729/stemcell.pdf Accessed 27/10/2005
26. Saldanha J (2004) NAT detection of blood borne viral markers in tissues from cadaver donors. On http://www. nibsc.ac.uk/partners/SoGAT/ 2004_Presentations.html Accessed 27/10/05
27. Schelhammer PF, Hershberg RM (2005) Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J Urol 23:47-49
28. See "Kate's Story" (2003) On http://www.cordblood.cryosite.com/ news.asp?id=4 Accessed 27/10/05
29. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. 343:230-238
30. Stanworth SJ, Warwick RM, Ferguson M, Barbara JA (2000) A UK survey of virological testing of cadaver tissue donors. Vox Sang 79:227-230
31. Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DB, Murphy MF (2004) Is fresh frozen plasma clinically effective? A systematic review of randomised controlled trials. Br J Haem 126:139-152
32. Taub JW, Konrad MA, Yubin G, Naber JM, Scott JS, Maherty LH, Ravindranath Y (2002) High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood 99:2992-2996
33. Therapeutic Goods Administration (2004) Summary of proposed framework for the regulation of cell and tissue therapies. On http://www.tga.gov.au/bt/prtisreg_sum.pdf Accessed 27/10/05
34. Valko N (2002) Ethical implications of non-heart-beating organ donation. On http://www.wf-org/02-3-organdonation.html Accessed 27/10/05
35. World Health Organisation (2003) Guidelines on transmissible spongiform encephalopathies in relation to biological and pharmaceutical products. On http://www.who.int/bloodproducts/publications/en/WHO_TSE_2003.pdf Accessed 27/10/05
36. Zou S, Dodd RV, Stramer SL, Strong DM, Tissue Safety Study Group (2004) Probability of viremia with HBV, HCV, HIV and HTLV among tissue donors in the United States. N Engl J Med 351:751-759